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Human Inflammatory Dendritic Epidermal Cells
Express a Functional Histamine H4 Receptor
Dorothea Dijkstra1, Holger Stark2, Paul L. Chazot3, Fiona C. Shenton3, Rob Leurs4, Thomas Werfel1 and
Ralf Gutzmer1
Expression of histamine H4 receptor (H4R) on leukocytes suggests an immunomodulatory role of this receptor.
Here we investigated the expression and function of H4R on human inflammatory dendritic epidermal cells
(IDECs). H4R is expressed by IDEC of the skin. On monocyte-derived IDECs (Mo-IDECs), H4R is also expressed
and upregulated by IFN-g. Functionally, histamine and H4R agonists clobenpropit and 4-methylhistamine
downregulated the production of the Th2-linked chemokine CCL2 and the Th1 cytokine IL-12 on Mo-IDEC,
whereas agonists for the other histamine receptors did not. An H4R-selective antagonist (JNJ7777120) blocked
the effect of H4R agonists. Downregulation of CCL2 also led to a decreased migration of monocytes. Thus, IDEC
express a functionally active H4R, which upon stimulation leads to downregulation of CCL2 and IL-12. This might
have implications for the treatment of atopic dermatitis, since H4R agonists may have beneficial effects in
downregulating inflammation.
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INTRODUCTION
Histamine plays an important role in skin inflammation. Its
actions are mediated via four histamine receptors, the
G-protein-coupled receptors H1R–H4R. All four receptors
are expressed by different subsets of haematopoietic cells and
have diverse functions. H1R and H2R are expressed by
conventional dendritic cells (DCs), such as monocyte-derived
DCs (Mo-DCs), and have been shown to be important for
T helper (Th) 1 and Th2 functions, respectively. H3R is
expressed by mast cells and its stimulation leads to down-
regulation of tumor necrosis factor-a (TNF-a) production by
these cells. The recently discovered histamine histamine H4
receptor (H4R) is expressed in leukocytes, in particular on
antigen-presenting cells (APCs) such as Mo-DC. Its stimula-
tion leads to downregulation of IL-12 and induces chemotaxis
of Mo-DC (Gutzmer et al., 2005). Data describing the
expression and function of the H4R on leukocytes present
in the skin of patients with chronic inflammatory skin
diseases, for example, atopic dermatitis (AD), are lacking.
AD is a complex disease in which allergic reactions to
aeroallergens and food allergens are regularly detectable. A
biphasic skin reaction is seen, the acute phase of which is
characterized by a Th2 response, whereas a Th1-dominated
response is seen in the chronic phase (Leung, 2000). The
pathogenic mechanisms behind this eczematous reaction are
unclear. The level of histamine in the affected as well as the
unaffected skin of AD patients is elevated as compared with
the skin of healthy individuals (Stander and Steinhoff, 2002).
In lesional skin of atopic dermatitis patients, a special DC
type occurs, namely the ‘‘inflammatory dendritic epidermal
cell’’ (IDEC) (Wollenberg et al., 1996). These cells disappear
after successful topical treatment of the skin (Wollenberg
et al., 2001). They are characterized by the expression of both
the low-affinity IgE receptor (CD23, FceRII) and the high-
affinity IgE receptor, FceRI (Wollenberg et al., 1998). IDECs
with activated FceRI (via binding and cross-linking of IgE)
have been shown to drive naive T-cell development toward
production of IFN-g-producing T cells by release of IL-12 and
IL-18 (Novak et al., 2004). Because of the importance of
IDECs in the pathogenesis of atopic dermatitis and a possible
interaction of histamine and IDECs in lesions of AD, we
investigated the expression and function of the H4R on IDECs.
RESULTS
Expression of H4R protein by skin IDECs and Mo-IDECs
Skin IDECs were identified in lesions of AD either by
immunofluorescence staining with CD36 or CD206 (FITC)
on paraffin sections or by flow cytometry of epidermal cell
suspensions (Figures 1 and 2). We chose CD206 as a marker
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Figure 1. Expression of the H4R by IDECs in skin sections. Skin sections (1 mm) of formalin-fixed and paraffin-embedded lesional AD skin biopsies were
stained with either FITC–CD36 or FITC–CD206 (to identify IDECs) and counterstained for the expression of the H4R (Texas Red). One representative experiment
of five is shown. Bar¼ 20mm.
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Figure 2. Expression of the H4R by IDECs in epidermal cell suspensions performed on freshly obtained shave biopsies from lesional AD skin. IDECs were
stained for CD206 (FITC) and H4R (peridinin–chlorophyll–protein complex), CD206-positive cells were gated and analyzed for H4R expression. (a) One
representative experiment is shown. GM, geometric mean of fluorescence. (b) Nine experiments are summarized. Statistical analysis was performed by
Wilcoxon’s signed-rank test; **Po0.005.
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for IDEC, since other cells present in the epidermis (such as
Langerhans cells) do not express CD206 (Wollenberg et al.,
2002), whereas other cells expressing CD206, such as
macrophages, are present in the dermis only. CD36 can also
be used to distinguish between IDECs and Langerhans cells
(Wollenberg et al., 1996). H4R was visualized by indirect
staining with streptavidin labelled with a peridinin–chlor-
ophyll–protein complex (PerCP) (epidermal cell supspen-
sions) or Texas Red (paraffin sections). As shown with these
techniques, CD36- or CD206-positive cells expressed the
H4R. For demonstrating the specificity of the H4R staining,
the antibody was blocked by preincubation with the
oligopeptide used to generate the antibody (van Rijn et al.,
2006; Figures 1 and 2). Also, keratinocytes express H4R
protein (Figure 1), which was also detected at mRNA levels
(data not shown).
Monocyte-derived IDECs (Mo-IDECs) also expressed H4R
protein (Figure 3). Furthermore, by stimulation with
20 ngml1 of IFN-g and combinations of IFN-g with
Polyinosinic–polycytidylic acid (poly I:C) and TNF-a, H4R
fluorescence was upregulated approximately threefold after
48 hours incubation, whereas IL-4, TNF-a, and poly I:C alone
did not show significant effects (Figure 3).
Inhibition of CCL2 production by Mo-IDECs via H4R activation
CCL2 production by Mo-IDECs was inhibited after H4R
agonist stimulation (Figure 4). CCL2 production was dose-
dependently inhibited by histamine (HA) and H4R agonists
clobenpropit (Clob) and 4-methylhistamine (4-MH) (Figure 4).
The IC50 value for HA was 32.6±19.8 nM, for Clob
11.1±6.6 nM, and for 4-MH 89.0±38.3 nM (average±SD).
The effects of these H4R agonists were inhibited by
JNJ7777120, an H4R-selective antagonist. Furthermore,
agonists of the H1R (b-histine), H2R (dimaprit), and H3R
(methimepip) did not inhibit CCL2 production (Figure 4).
These results confirm that the downregulation of CCL2 was
solely mediated via the H4R. The inhibition of CCL2
production by H4R stimulation on Mo-IDECs was already
visible in the supernatants after 2 hours of incubation with
4-MH, and was blocked by co-incubation with JNJ7777120.
This inhibition was even more pronounced after 4, 24, and
48 hours of incubation (Figure S2).
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Figure 3. Expression and regulation of the H4R on Mo-IDECs. (a) Staining of H4R (thick line), isotype (gray filled thin line), and blocked H4R antibody (thin line).
(b) Regulation of H4R expression by IFN-g (20 ngml
1), IL-4 (20 ngml1), TNF-a (0.5 ngml1), poly I:C (TLR3 ligand, 2 mgml1), or combinations of these
(mean±SEM of five independent experiments is shown). Statistical analysis was performed by ANOVA; **Po0.005. (c) Upregulation by IFN-g, IFN-gþ TNF-a
and IFN-gþ TNF-a and IFN-gþ TNF-aþ poly I:C (thick lines) as compared with non-stimulated cells (thin lines) in one representative experiment.
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CCL2 synthesis and secretion by Mo-IDECs is inhibited via H4R
activation
We investigated the level at which CCL2 production by Mo-
IDECs was inhibited by H4R agonists. CCL2 mRNA was
downregulated in Mo-IDEC incubated with H4R agonists for
4 hours at 10 mM (Figure S3). Furthermore, when the cells
were incubated with the most selective H4R ligand 4-MH for
2–4 hours at 10 mM, the intracellular level of CCL2 as
determined by intracellular staining and flow cytometry was
higher than in non-stimulated cells (Figure S3). After 24 and
48 hours of incubation, 4-MH (10 mM) reduced intracellular
CCL2 content as compared with that of non-stimulated cells.
Chemotaxis of monocytes to Mo-IDEC culture supernatants
The medium from H4R-stimulated Mo-IDECs (48 hours)
attracted fewer monocytes than the medium from non-
stimulated cells (Figure 5). This effect was most probably
caused by reduced amounts of CCL2 in the supernatants, as
chemotaxis toward non-stimulated monocyte medium was
inhibited by a neutralizing CCL2 antibody. Addition of
human recombinant CCL2 to the H4R agonist-stimulated
monocyte media re-induced chemotaxis. For control experi-
ments, fresh medium with HA, Clob, or 4-MH did not induce
chemotaxis of monocytes.
Inhibition of IL-12p40 (IL-12p40) production by Mo-IDECs via
H4R activation
Since CCL2 is associated with Th2 polarization, we also
tested the effect of H4R stimulation on IL-12 as a classical Th1
cytokine. IL-12 has been shown to be downregulated via the
H4R on classical Mo-DCs (Gutzmer et al., 2005). IL-12p40
production by Mo-IDECs was inhibited after incubation with
HA and the H4R agonist 4-MH. Dimaprit, an H2R agonist,
also inhibited IL-12p40 production. The downregulation of
IL-12p40 production by HA and 4-MH was blocked by co-
incubation with JNJ7777120 (Figure 6).
DISCUSSION
In this study, we investigated the expression and function of
the H4R on human IDEC present in lesional skin of AD
patients. An interaction between HA and IDEC is suggested
by the presence of high levels of HA in the skin of AD patients
(Stander and Steinhoff, 2002). Some H4R-mediated effects of
HA on APCs have been demonstrated before, for example,
IL-12 downregulation in human Mo-DCs (Gutzmer et al.,
2005) and CCL2 downregulation in human monocytes
(Dijkstra et al., 2007). We show here that skin IDECs express
the H4R at the protein level, as shown by flow cytometry of
epidermal cell suspensions and immunofluorescence staining
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Figure 4. Histamine downregulates CCL2 protein via H4R. Mo-IDECs were stimulated with HA or agonists of H1R (b-histine; b his), H2R (dimaprit; Dim), H3R
(methimepip; MP), and H4R (Clob and 4-MH), for 48 hours at 10mM or at the indicated concentrations. JNJ7777120 (JNJ) was used as an H4R-neutral antagonist.
CCL2 was measured by ELISA, normalized to non-stimulated cells: 3,261±1,902 ngml1 (mean±SEM). (a) HA downregulated CCL2 solely via H4R.
(b) Dose–response curves of CCL2 downregulation by HA, Clob, and 4-MH. Mean±SEM of five different experiments are shown. Statistical analysis was
performed by ANOVA; *Po0.05, **Po0.005.
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of skin sections from lesional skin of AD patients. The
functional investigation of skin IDECs is hampered by their
low number in the skin, and therefore IDECs were generated
from monocytes following a published protocol (Novak et al.,
2002). In this study, blood from healthy anonymous donors
was used because these individuals have lower levels of HA
in their blood (compared to atopic individuals), which could
interfere either with the generation of proper Mo-IDECs or
with the experiments performed with them. They expressed
CD1a, CD23, CD36, CD206, and the FceRI-a, but not CD14
or CD83. This is consistent with the characteristics of
Mo-IDECs (Novak et al., 2002). The expression of CD86 by
the Mo-IDECs in our study is in contrast to the previous study.
However, it is in agreement with high levels of CD86
expression reported in skin IDECs (Schuller et al., 2001).
Furthermore, Mo-IDECs were not mature, as indicated by the
lack of CD83 expression and the absence of IL-12 and TNF-a
production without a maturation stimulus (results not shown).
Total IgE levels in the blood of all the blood donors were
measured. A correlation between total IgE levels and the
expression of the FceRI-a was not found (Figure S1). This is
not in contrast with earlier results published by the Novak
et al. (2002) because here FceRI-a expression and IgE levels
of atopic donors were measured and no healthy, non-atopic
donors were included.
The expression of H4R on Mo-IDECs was upregulated by
interferon-g but not by IL-4, TNF-a, poly I:C, or combinations
of these, thus demonstrating that H4R has a role in a Th1
milieu. Common Mo-DCs expressed the H4R at similar levels,
and IFN-g also induced H4R expression (results not shown).
H4R is functional since its stimulation specifically and dose-
dependently downregulated basal CCL2 production and
secretion. There was no change in surface marker expression
on the IDECs after 48 hours of incubation with 4-MH (10 mM).
This supports the fact that the downregulation of CCL2 is not
merely a change in phenotype of the cells. The high basal
level of CCL2 observed in our study is in contrast to the lower
levels of CCL2 produced by IDEC observed by Novak et al.
(2002). Novak et al. (2002) cultured 2.5 105 cellsml1 per
well in a 24-well plate, whereas we stimulated 2105 cells
per 300ml per well. Thus, the major difference in basal CCL2
concentrations might be explained by different concentra-
tions of cells.
High CCL2 levels have been linked to Th2 responses in
previous studies. CCL2 can, for example, be induced in
human primary keratinocytes upon stimulation by the Th2
cytokine IL-13 (Purwar et al., 2006). A polymorphism in the
promoter region of CCL2 (leading to high CCL2 levels) was
associated with a severe asthma phenotype (Szalai et al.,
2001). Furthermore, in mice lacking CCL2, attraction of
macrophage sites of inflammation was disturbed and antigen-
specific Th1 cells produced less IFN-g (Huang et al., 2001). In
mice lacking CCR2 (the receptor for CCL2), an enhanced
airway Th2 response was found (manifested by eosinophilia,
Ig subclass switching, and IL-5 production) (Kim et al., 2001).
The upregulation of the H4R by IFN-g and the down-
regulation of CCL2 by H4R agonists suggest a role of the
H4R in a Th1 response. This blockade of CCL2 could
contribute to the shift from the Th2 to the Th1 milieu seen
in the transition from acute to chronic AD (Leung, 2000).
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Since CCL2 is associated with a Th2 milieu, we also studied
IL-12 as a classical Th1 cytokine produced by Mo-IDECs.
IL-12p40 was also downregulated via the H4R on Mo-IDECs.
This is consistent with our data on Mo-DCs (Gutzmer, 2005)
and points toward a general anti-inflammatory role of the
H4R affecting both Th1 and Th2 immune responses.
We studied the effect of H4R agonist stimulation on
chemotaxis toward supernatants of IDECs and observed
significantly lower monocyte migration levels into super-
natants from cells incubated with H4R agonists as compared
with that of non-stimulated Mo-IDECs. CCL2 is a chemokine
for monocytes, activated T lymphocytes, and natural killer
cells (Sozzani et al., 1995). Therefore, the downregulation of
CCL2 by HA may represent a negative feedback mechanism
to inhibit an overwhelming immune response. In summary,
the H4R is functionally expressed on IDECs, which suggests
an immunomodulatory role in AD. Functionally, this receptor
appears to limit the immune response by downregulating
both Th1- and Th2-related mediators as well as chemotactic
activity, and could therefore represent an interesting target for
anti-inflammatory therapies.
MATERIALS AND METHODS
Chemicals
Histamine (H1R–H4R agonist; ALK Scherax, Hamburg, Germany),
b-histine (H1R agonist; Sigma-Aldrich, Deisenhofen, Germany),
dimaprit (H2R agonist; Sigma-Aldrich), methimmepip (H3R agonist)
Clob (H4R agonist, H3R antagonist; Sigma-Aldrich) (Barnes et al.,
1993), 4-MH (H4R agonist) (Lim et al., 2005), and JNJ7777120 (H4R-
neutral antagonist) (Jablonowski et al., 2003) were used at 10 mM
unless otherwise stated. Methimmepip, 4-MH, and JNJ7777120
were synthesized as described previously (Jablonowski et al., 2004;
Kitbunnadaj et al., 2005; Lim et al., 2005). Poly I:C (2 mgml1;
Sigma-Aldrich), TNF-a (0.5 ngml1; Immunotools, Friesoythe,
Germany) IFN-g (20 ngml1; Immunotools), and IL-4 (20 ngml1;
R&D Systems, Wiesbaden, Germany) were used in H4R regulation
studies. Neutralizing anti-CCL2 was obtained from R&D Systems.
CCL2 was obtained from TebuBio (Offenbach, Germany).
The polyclonal rabbit anti-hH4R antibody has been described
previously (van Rijn et al., 2006; Dijkstra et al., 2007). The antibody
recognizes amino acids 374–390 (antigenic peptide obtained from
Sigma-Genosys, Cambridge, UK), which is positioned in the
intracellular tail of the human H4R.
Differentiation of Mo-IDECs
Buffy coats from anonymous healthy blood donors obtained from the
local blood bank were used. The buffy coats were disposed off by the
blood bank after thrombocyte preparation. Total IgE levels as well as
IgE against the common aeroallergens (sx-1, determination of
specific IgE against weeds, grasses, trees, cat and dog epithelia,
Cladosporium sp., and Dermatophagoides sp.) were measured (CAP
system; Pharmacia, Freiburg, Germany) and were below the normal
limits of 100 and 0.35 kU l1, respectively.
Peripheral blood mononuclear cells were separated from
heparinized buffy coats by density-gradient centrifugation on
lymphoprep (Fresenius Kabi Norge AS, Oslo, Norway). Adherent
cells were obtained by plastic adherence: 1 108 peripheral blood
mononuclear cells were plated in 80-cm2 culture flasks (NuclonTMD;
Nunc GmbH & Co. AG, Wiesbaden, Germany) in Iscove medium
supplemented with 5% v/v AB (serum from blood group AB), 1% w/v
non-essential salts, 2mM L-glutamine, 100Uml1 penicillin,
100mgml1 streptomycin, and 0.5% w/v gentamycin (all from
Biochrom AG, Berlin, Germany) for 1 hour (37 1C, 5% CO2,
humidified atmosphere). The adherence of monocytes was more
effective in this medium as compared with that in the IDEC medium
(for media preparation see below). Then the non-adherent cells were
removed by vigorous washing with phosphate-buffered saline (PBS).
The adherent cells (enriched monocytes, purity at least 85%) were
further cultured in RPMI 1640 medium supplemented with 5% v/v
fetal calf serum, 12mM HEPES, 2mM L-glutamine, 100Uml1
penicillin, 100mgml1 streptomycin, IL-4 (10 ngml1; R&D Sys-
tems) granulocyte–monocyte colony-stimulating factor (50 ngml1;
Berlex Pharmaceutical Company, Montville, NJ), and 50 mM
b-mercapthoethanol (Sigma-Aldrich) (IDEC medium). This is the
standard medium for the generation of Mo-IDECs (Novak et al.,
2002). The medium was changed every 2 days and the cells were
harvested on day 8. The cells were characterized by staining the
following surface molecules: CD1a (BD Biosciences, Bedford, MA),
CD14, CD23, CD36, CD40, CD54, CD80, CD83, CD86 (all from
Beckman Coulter, Krefeld, Germany), CD206 (BD Biosciences),
HLA-DR (BD Biosciences), and FceRIa (Upstate, Temecula, CA).
Control staining was performed with unlabelled (Beckman Coulter),
FITC-, and phycoerythrin-labelled (Sigma-Aldrich) mouse IgG1
antibodies, with FITC- and phycoerythrin-labelled mouse IgG2a
antibodies (Sigma-Aldrich) and FITC-, phycoerythrin- (Sigma-
Aldrich), and allophycocyanin- (BD Biosciences)-labelled mouse
IgG2b antibodies. Mo-IDECs were regarded as differentiated
immature cells, since CD1a, CD23, CD36, CD206, and FceRIa,
but not CD14 or CD83, were expressed. The surface markers
were measured on each Mo-IDECs preparation in order to assure
their state of differentiation. Of 70 donors initially included for
the study, 25% had IgE levels higher than 100 kU l1. The cells
from these atopic donors were not used for the experiments
described in this paper, but were presented in Figure S1. No
correlation of FceRI-a expression levels to total IgE levels was found
(Figure S1).
Immunofluorescence staining of H4R on IDEC in human skin
Paraffin sections (1mm) from skin biopsies from chronic lesions of
atopic dermatitis patients were transferred to SuperFrost microscope
slides (Menzel-Gla¨ser, Braunschweig, Germany). The sections were
deparaffinated, rehydrated, and transferred to a citrate-containing
target retrieval solution (Dako Cytomation, Hamburg, Germany),
and incubated overnight at 70 1C. After cooling the slides to room
temperature, the sections were incubated with PBS-containing goat
serum (Vectastain ABC kit, alkaline phosphate rabbit IgG; Vector
Laboratories, Burlingame, CA) and incubated for 1.5 hours at room
temperature. Following this, the slides were incubated with
200 ngml1 rabbit anti-human-H4R antibody, H4R antibody blocked
with a 10-fold higher concentration of antigenic peptide (used to
generate the antibody) (van Rijn et al., 2006), or isotype overnight at
4 1C. Next, the slides were washed twice in PBS (2 5minutes),
incubated for 1 hour in secondary antibody (biotinylated goat anti-
rabbit antibody, Vectastain ABC kit, alkaline phosphatase rabbit IgG;
Vector Laboratories), followed by washing and consecutive
staining with 10 mgml1 Texas Red-coupled streptavidin (Vector
www.jidonline.org 1701
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Laboratories). Then the sections were incubated again in PBS-
containing goat serum for 1 hour in the dark at room temperature.
This was followed by staining with either anti-CD36 or CD206
(Immunotech, Marseille, France and BD Biosciences, respectively)
overnight at 4 1C. After washing (2 5minutes in PBS), mounting
medium (Vectashield; Vector Laboratories) and coverslips were
added to the sections. Fluorescence images were obtained with a
Zeiss Axiolab microscope with AxioCam MRm and images were
acquired with the program AxioVS40 (version 4.6.1.0) (Carl Zeiss
MicroImaging GmbH, Go¨ttingen, Germany).
Staining of H4R on Mo-IDECs and IDECs in human epidermal
cell suspensions
After receiving written informed consent from patients, shave
biopsies were taken from chronic eczematous skin lesions of AD
patients. The study was approved by the local ethics committee and
was in accordance with the protocols of the Declaration of Helsinki
Principles. The patients included in the study (5 females and 4 males)
were not treated before the biopsies were taken. The age of the
patients ranged from 19 to 87 years (average 54±24 years). Under
local anesthesia, superficial shave biopsies of the epidermis
(2–4 cm2) were obtained and immediately processed. Shave biopsies
were transferred into sterile PBS and cut in small pieces. Then the
shave biopsies obtained were incubated in trypsin–EDTA for
10minutes and the reaction was stopped with inactivated fetal calf
serum. Cells were separated by transferring them over a 40-mm nylon
cell strainer (BD Biosciences). The flow through was centrifuged
(10minutes 1,300 r.p.m.) and the pellet was washed twice with PBS.
The cells were incubated overnight in supplemented Iscove medium
(37 1C, 5% CO2). The next day they were washed twice in PBS and
incubated in PBS containing human IgG (FcgR-blocking buffer,
30minutes on ice). Then the cells were stained (in blocking buffer)
with FITC-labelled IgG1 isotype or CD206 (30minutes on ice). The
Mo-IDECs and skin suspensions were (counter-) stained for H4R
according to the protocol and with the reagents provided by BD
Biosciences (Heidelberg, Germany) for intracellular epitope-directed
antibodies. In brief, cells were fixed and permeabilized. Sub-
sequently, the cells were labelled with (1) 200 ngml1 H4R
antibody, (2) polyclonal rabbit isotype antibody, or (3) H4R antibody
preincubated with a 10-fold higher concentration of antigenic
oligopeptide used to generate the antibody (van Rijn et al., 2006).
This was followed by labelling with goat anti-rabbit antibody
conjugated with biotin (Jackson ImmunoResearch Laboratories,
Suffolk, UK). Final staining was performed with streptavidin coupled
with peridinin–chlorophyll–protein complex (BD Biosciences), and
the H4R positivity of the cells was quantified by flow cytometry
(FACS Calibur; Becton Dickinson, Heidelberg, Germany). Relative
fluorescence intensities (RFI) of the IDEC in skin suspensions
obtained by flow cytometry were calculated from the mean
fluorescence intensity (MFI) values according to the following
formula (Novak et al., 2002):
RFI¼ (MFI surface stainingMFI isotype control)/MFI isotype
control.
CCL2 and IL-12p40 ELISA
Mo-IDECs were plated in IDEC medium on a 24-well plate (2 105
per well per 300ml) and were incubated in RPMI supplemented with
ligands for 48 hours (37 1C, 5% CO2). Supernatants were taken and
CCL2 and IL-12p40 were detected by ELISA, according to the
manufacturer’s instructions (CCL2: TebuBio; detection limits
8–3,000 pgml1; IL-12p40: duoset from R&D Systems, detection
limits 31.2–2,000 pgml1). The plates were read at a wavelength of
405 nm on a FluoStar plate reader (BMG Lab Technologies, GmbH,
Jena, Germany).
CCL2 intracellular staining
To measure the amounts of intracellular CCL2, adherent cells (from
1 106 peripheral blood mononuclear cells per well) were
stimulated with 10 mM H4R ligands for 2, 4, 24, or 48 hours (37 1C,
5% CO2). Cells were detached with trypsin–EDTA (37 1C, 5% CO2)
and the reaction was stopped with an equal volume of heat-
inactivated fetal calf serum after 10minutes. The viability of the cells
was assessed by staining with trypan blue (495%). Then the cells
were washed twice with PBS and intracellular CCL2 was stained
according to the protocol provided by BD Biosciences for
intracellular staining. In brief, cells were fixed and permeabilized
and then stained with the allophycocyanin-labelled anti-CCL2
antibody (50 ngml1, IgG2B, clone 23002) or an allophycocyanin-
labelled isotype control antibody (IgG2B) for 30minutes at 4 1C. The
cells were washed and CCL2 positivity was quantified by flow
cytometry.
CCL2 quantitative PCR
Total RNA was isolated from 2 105 IDECs according the
manufacturer’s instructions, using the High Pure mRNA Isolation
kit (Roche Molecular Biochemicals, Mannheim, Germany). The
cDNA was synthesized by reverse transcription (Quantitects reverse
transcription kit; Qiagen, Hilden, Germany). Real-time quantitative
PCR was performed with Quantitect primer assays for CCL2
(QT00212730) and glyceraldehyde-3-phosphate dehydrogenase
(QT00079247), using SYBRs Green, according to the manufac-
turer’s instructions (Qiagen). A genomic DNA digestion step was
included in this kit.
The following settings were used in the LightCycler PCR: an
initial activation step of 15minutes at 95 1C and a ramp of 20 1C s1
was followed by three-step cycling (42 cycles) consisting of the
following: denaturation (15 seconds at 94 1C), annealing (20 seconds
at 55 1C) and extension (20 seconds at 72 1C) (all three with a ramp of
2 1C s1). The melting curve analysis was conducted at 60–90 1C
(ramp: 20 1C s1). The amounts of the CCL2 relative to the amount of
the reference glyceraldehyde-3-phosphate dehydrogenase in the
same sample was calculated by the relative quantification approach
using the software provided by the manufacturer (Roche, Marseille,
France). Mathematically, the result for each sample is expressed as
the ratio of CCL2 and glyceraldehyde-3-phosphate dehydrogenase
derived from the crossing points, which are obtained in the
Lightcycler software (version 1.0; Roche). In addition, since the
basal levels of CCL2 were different for each individual donor,
the data were normalized to the CCL2 level in the non-stimulated
sample (100%). The values obtained for H4R agonist-stimulated
Mo-IDECs were then expressed as the percentage of the non-
stimulated monocytes.
Chemotaxis bioassay
Chemotaxis of monocytes was measured over polycarbonate
membranes with pore diameter of 5mm (Corning Inc./Costar,
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New York, NY). A volume of 600 ml of supernatant from cultured and
stimulated Mo-IDECs (with 10 mM stimuli and neutralizing anti-CCL2
antibody as indicated in the text) was used as a chemoattractant in
the lower chamber. The upper chamber with the membrane was
filled with 250 ml medium with 106 isolated monocytes. Chemotaxis
was allowed for 1.5 hours and the number of transmigrated cells was
counted after staining with trypan blue (Sigma-Aldrich) in a
Burker–Tu¨rk counting chamber. Controls were conducted as
described in the text and figures.
Statistics
Wilcoxon signed-rank test and analysis of variance (ANOVA)
(Bonferonni multiple comparison test) were used, and a P-value less
than 0.05 was considered significant (Po0.05 was indicated by *
and Po0.005 was indicated by **). The GraphPad Prism program
version 3.02 was used for statistical analyses.
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SUPPLEMENTARY MATERIAL
Figure S1. Total IgE and FceRI-a levels of 71 blood donors.
Figure S2. Kinetics of CCL2 downregulation by the H4R agonist 4-MH.
JNJ7777120 (JNJ) blocked CCL2 inhibition.
Figure S3. Histamine downregulates CCL2 synthesis and secretion.
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